Analyst consensus rating
Mineralys Therapeutics Analyst Rating: Strong Buy
Direct answer
Mineralys Therapeutics's consensus rating is Strong Buy.
9 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $46.33.
Forecast evidence checked October 19, 2026.
Get free Mineralys Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $20.30
- Average price target
- $46.33
- High price target
- $56.00
- Low price target
- $29.00
- Low target gap
- +42.9%
- Target upside
- +128.2%
- High target gap
- +175.9%
- Target range width
- 133%
- Consensus rating
- Strong Buy
- Analysts
- 9
- Evidence date
- October 19, 2026
- Valid through
- October 26, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Mineralys Therapeutics?
Mineralys Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $46.33.
How far are Mineralys Therapeutics's low and high targets from the recorded price?
The low target implies +42.9%, while the high target implies +175.9%.
How many analysts are included in Mineralys Therapeutics's consensus?
The verified consensus includes 9 analysts.
How is Mineralys Therapeutics's target upside or downside calculated?
The average target of $46.33 is divided by the recorded price of $20.30, then one is subtracted to produce +128.2%. This does not guarantee a future return.
When was Mineralys Therapeutics's analyst forecast verified?
The data was verified on 2026-10-19. The dataset is valid through 2026-10-26.